Moun Biotech Secures Over RMB 100 Million Series B+ Financing Led by Sequoia China to Accelerate Microbiome Industrialization

Recently, Guangzhou Colony Biotechnology Co., Ltd. (hereinafter referred to as “Colony Bio”) completed a Series B+ financing round exceeding RMB 100 million, led by Sequoia China Fund. The proceeds from this round will be primarily used to leverage the advantages of the company’s microbiome technology platform, accelerate the industrialization of multiple R&D pipelines, including advancing the clinical trials of two innovative live biotherapeutic products, and promoting the market development and sales of various agricultural microbial products.

Founded in 2015, Guangzhou Colony Biotechnology Co., Ltd. is an internationally leading microbiome platform technology company that has established a complete industrialization technology system for the microbiome, encompassing microbial discovery, screening, engineering, and application. The company has built the world’s largest and most biodiverse gut and plant microbial strain and gene libraries, having discovered, preserved, and identified over 140,000 microbial strains with independent intellectual property rights. Leveraging its proprietary Culture-To-Product technology platform, Colony Biotechnology can efficiently and continuously develop innovative, naturally derived, high-activity microbes and their metabolites. In the biopharmaceutical sector, the company is targeting the therapeutic potential of microbiome-based therapies in tumor immunology and metabolic diseases, and is building a research and development pipeline comprising nine blockbuster live biotherapeutic products.Its oncology immunotherapy pipeline MNC-168 and metabolic disease pipeline MNO-863 are scheduled to file Investigational New Drug (IND) applications in both China and the United States this year, with the potential to become the first live biotherapeutic products in China to enter clinical trials in their respective fields.In the bio-agriculture sector, Guangzhou Colony Biotechnology Co., Ltd. has a clear commercialization pathway, targeting a $60 billion unmet market for crop and soil health, and has obtained product certificates and registered more than ten bio-agricultural products.The company has launched a series of highly innovative agricultural microbial inoculant products,and has established commercial partnerships with multiple leading enterprises in the industry, achieving a threefold increase in product sales revenue for two consecutive years.

Dr. Xianzhi Jiang, Founder & CEO of Colony BiotechnologyStatement: This year is a critical one for validating the technological platform advantages and industrial value of Colony Biotechnology. We sincerely appreciate the support and trust from Sequoia China. With the backing of both existing and new shareholders, Guangzhou Colony Biotechnology Co., Ltd. will continue to strengthen its technological and industrial strengths, including enhancing capabilities in microbial multi-omics and single-strain genomic data mining and prediction, expanding the clinical drug development team, and broadening the market channel network for bio-agricultural products. In 2021, Colony Biotechnology is poised to achieve greater breakthroughs in technological innovation and industrialization.

Sequoia Capital has always been committed to helping entrepreneurs build enduring, great companies by providing its portfolio companies with abundant global resources and valuable historical experience. Over the past 49 years, Sequoia Capital has invested in numerous innovative enterprises and leaders shaping industry trends. As “entrepreneurs behind entrepreneurs,” Sequoia Capital China focuses on investment opportunities in three key sectors: TMT (Technology, Media, and Telecom), healthcare, and consumer goods/services. Over the past 16 years, Sequoia Capital China has invested in nearly 600 companies characterized by distinct technological advantages, innovative business models, and high growth potential.